Ikeda Osama, Tamura Yoshitaka, Nakasone Yutaka, Shiraishi Shinya, Kawanaka Kouichi, Tomiguchi Seiji, Yamashita Yasuyuki, Takamori Hiroshi, Kanemitsu Keiichiro, Baba Hideo
Department of Diagnostic Radiology, Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, 1-1-1, Honjo Kumamoto 860-8556, Japan.
Cardiovasc Intervent Radiol. 2007 Sep-Oct;30(5):912-21. doi: 10.1007/s00270-007-9134-2. Epub 2007 Aug 21.
The purpose of this study was to compare intrahepatic and pancreatic perfusion on fusion images using a combined single-photon emission computed tomography (SPECT)/CT system and to evaluate the efficacy of combined continuous transcatheter arterial infusion (CTAI) and systemic chemotherapy in the treatment of advanced pancreatic carcinoma.
CTAI was performed in 33 patients (22 men, 11 women; age range, 35-77 years; mean age, 60 years) with stage IV pancreatic cancer with liver metastasis. The reservoir was transcutaneously implanted with the help of angiography. The systemic administration of gemcitabine was combined with the infusion of 5-fluorouracil via the reservoir. In all patients we obtained fusion images using a combined SPECT/CT system. Pancreatic perfusion on fusion images was classified as perfusion presence or as perfusion absent in the pancreatic cancer. Using WHO criteria we recorded the tumor response after 3 months on multislice helical CT scans. Treatment effects were evaluated based on the pancreatic cancer, liver metastasis, and factors such as intrahepatic and pancreatic perfusion on fusion images. For statistical analysis we used the chi-square test; survival was evaluated by the Kaplan Meier method (log-rank test).
On fusion images, pancreatic and intrahepatic perfusion was recorded as hot spot and as homogeneous distribution, respectively, in 18 patients (55%) and as cold spot and heterogeneous distribution, respectively, in 15 (45%). Patients with hot spot in the pancreatic tumor and homogeneous distribution in the liver manifested better treatment results (p < 0.05 and p < 0.01, respectively). Patients with hot spot both in the pancreatic cancer and in the liver survived longer than those with cold spot in the pancreatic cancer and heterogeneous distribution in the liver (median +/- SD, 16.0 +/- 3.7 vs. 8.0 +/- 1.4 months; p < 0.05).
We conclude that in patients with advanced pancreatic cancer, CTAI with systemic chemotherapy appeared to be effective and may prolong their survival. The development of a reservoir port system allowing for the homogeneous distribution of anticancer drugs is necessary to improve the prognosis of patients with advanced pancreatic cancer.
本研究旨在使用单光子发射计算机断层扫描(SPECT)/CT联合系统比较融合图像上的肝内和胰腺灌注情况,并评估持续经导管动脉灌注(CTAI)联合全身化疗治疗晚期胰腺癌的疗效。
对33例伴有肝转移的IV期胰腺癌患者(22例男性,11例女性;年龄范围35 - 77岁,平均年龄60岁)进行CTAI。在血管造影辅助下经皮植入储液器。吉西他滨全身给药联合通过储液器输注5-氟尿嘧啶。所有患者均使用SPECT/CT联合系统获取融合图像。融合图像上的胰腺灌注分为胰腺癌中有灌注或无灌注。使用WHO标准,在3个月后通过多层螺旋CT扫描记录肿瘤反应。基于胰腺癌、肝转移以及融合图像上的肝内和胰腺灌注等因素评估治疗效果。统计学分析采用卡方检验;生存情况通过Kaplan Meier方法(对数秩检验)进行评估。
在融合图像上,18例患者(55%)的胰腺灌注记录为热点,肝内灌注记录为均匀分布,15例患者(45%)的胰腺灌注记录为冷点,肝内灌注记录为不均匀分布。胰腺肿瘤为热点且肝脏为均匀分布的患者表现出更好的治疗效果(分别为p < 0.05和p < 0.01)。胰腺癌和肝脏均为热点的患者比胰腺癌为冷点且肝脏为不均匀分布的患者生存时间更长(中位数±标准差,16.0±3.7 vs. 8.0±1.4个月;p < 0.05)。
我们得出结论,对于晚期胰腺癌患者,CTAI联合全身化疗似乎有效且可能延长其生存期。开发一种能使抗癌药物均匀分布的储液器端口系统对于改善晚期胰腺癌患者的预后是必要的。